Michael W Lutz

List of Publications by Citations

99 papers	**2,149** citations	**27** h-index	**44** g-index
110 ext. papers	**2,529** ext. citations	**3.8** avg, IF	**4.62** L-index

#	Paper	IF	Citations
99	The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy. *Journal of Theoretical Biology*, **1996**, 181, 381-97	2.3	176
98	The Cubic Ternary Complex Receptor‐Occupancy Model I. Model Description. *Journal of Theoretical Biology*, **1996**, 178, 151-167	2.3	165
97	Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. *Journal of Medicinal Chemistry*, **1991**, 34, 2202-8	8.3	162
96	Novel loci and pathways significantly associated with longevity. *Scientific Reports*, **2016**, 6, 21243	4.9	105
95	The Cubic Ternary Complex Receptor‐Occupancy Model II. Understanding Apparent Affinity. *Journal of Theoretical Biology*, **1996**, 178, 169-182	2.3	92
94	The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ℇ3/ℇ3 genotype. *Alzheimer's and Dementia*, **2011**, 7, 456-65	1.2	86
93	Genetic variation at a single locus and age of onset for Alzheimer's disease. *Alzheimer's and Dementia*, **2010**, 6, 125-31	1.2	68
92	The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes. *Alzheimer's and Dementia*, **2014**, 10, 541-51	1.2	55
91	Peak alignment of urine NMR spectra using fuzzy warping. *Journal of Chemical Information and Modeling*, **2006**, 46, 863-75	6.1	55
90	Longitudinal modeling of cognitive aging and the TOMM40 effect. *Alzheimer's and Dementia*, **2012**, 8, 490-5	1.2	50
89	TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. *Alzheimer's and Dementia*, **2013**, 9, 132-6	1.2	49
88	Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. *Neurobiology of Aging*, **2014**, 35, 1513.e25-33	5.6	47
87	New applications of disease genetics and pharmacogenetics to drug development. *Current Opinion in Pharmacology*, **2014**, 14, 81-9	5.1	46
86	Characterization of the poly-T variant in the TOMM40 gene in diverse populations. *PLoS ONE*, **2012**, 7, e30994	3.7	42
85	The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging **2014**, 1,		41
84	A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging. *Alzheimer's and Dementia*, **2012**, 8, 381-8	1.2	41
83	Experimental design for high-throughput screening. *Drug Discovery Today*, **1996**, 1, 277-286	8.8	40

64	A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression. *Alzheimer's and Dementia*, **2015**, 11, 1133-43	1.2	17
63	Shared genetic etiology underlying Alzheimer's disease and major depressive disorder. *Translational Psychiatry*, **2020**, 10, 88	8.6	17
62	Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. *Journal of the Neurological Sciences*, **2016**, 365, 89-95	3.2	17
61	Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 135-47	5.5	16
60	Bioinformatics strategy to advance the interpretation of Alzheimer's disease GWAS discoveries: The roads from association to causation. *Alzheimer's and Dementia*, **2019**, 15, 1048-1058	1.2	15
59	The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 661-670	6	15
58	Cerebrospinal fluid cortisol concentrations in healthy elderly are affected by both APOE and TOMM40 variants. *Psychoneuroendocrinology*, **2012**, 37, 366-71	5	14
57	Investigating Predictors of Cognitive Decline Using Machine Learning. *Journals of Gerontology - Series B Psychological Sciences and Social Sciences*, **2020**, 75, 733-742	4.6	14
56	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Neurology, The*, **2021**, 20, 537-547	24.1	13
55	A systems-based model of Alzheimer's disease. *Alzheimer's and Dementia*, **2019**, 15, 168-171	1.2	12
54	Effect of APOE and CD33 on Cognitive Decline. *PLoS ONE*, **2015**, 10, e0130419	3.7	12
53	The correlation of copy number variations with longevity in a genome-wide association study of Han Chinese. *Aging*, **2018**, 10, 1206-1222	5.6	12
52	Interaction Between the FOXO1A-209 Genotype and Tea Drinking Is Significantly Associated with Reduced Mortality at Advanced Ages. *Rejuvenation Research*, **2016**, 19, 195-203	2.6	10
51	Family history and TOMM40 '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts. *Alzheimer's and Dementia*, **2017**, 13, 1217-1225	1.2	10
50	Neighborhoods, sleep quality, and cognitive decline: Does where you live and how well you sleep matter?. *Alzheimer's and Dementia*, **2018**, 14, 454-461	1.2	10
49	Characterization of and allele frequencies in the Japanese population. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 524-530	6	10
48	APOE/TOMM40 genetic loci, white matter hyperintensities, and cerebral microbleeds. *International Journal of Stroke*, **2015**, 10, 1297-300	6.3	10
47	The SSV Evaluation System: A Tool to Prioritize Short Structural Variants for Studies of Possible Regulatory and Causal Variants. *Human Mutation*, **2016**, 37, 877-83	4.7	10

46	Neuropathologic features of TOMM40 '523 variant on late-life cognitive decline. *Alzheimer's and Dementia*, **2017**, 13, 1380-1388	1.2	9
45	Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers. *Expert Review of Precision Medicine and Drug Development*, **2017**, 2, 47-55	1.6	8
44	Analysis of pleiotropic genetic effects on cognitive impairment, systemic inflammation, and plasma lipids in the Health and Retirement Study. *Neurobiology of Aging*, **2019**, 80, 173-186	5.6	8
43	Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome. *Alzheimer's and Dementia*, **2020**, 16, 1280-1292	1.2	6
42	Translocase of outer mitochondrial membrane 40 homolog (TOMM40) poly-T length modulates lorazepam-related cognitive toxicity in healthy APOE 4-negative elderly. *Journal of Clinical Psychopharmacology*, **2011**, 31, 544-6	1.7	6
41	The importance of being connected. *Journal of Alzheimer's Disease*, **2011**, 24, 247-51	4.3	6
40	KRAX is important operational determinant of tissue response. KRAX as parameter for classification. *Trends in Pharmacological Sciences*, **1988**, 9, 351	13.2	6
39	Interaction between APOE 4 and dietary protein intake on cognitive decline: A longitudinal cohort study. *Clinical Nutrition*, **2021**, 40, 2716-2725	5.9	5
38	APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid. *Journal of Alzheimer's Disease*, **2021**, 79, 511-530	4.3	4
37	Genetic and non-genetic factors associated with the phenotype of exceptional longevity & normal cognition. *Scientific Reports*, **2020**, 10, 19140	4.9	3
36	The association between neighborhood socioeconomic status, cardiovascular and cerebrovascular risk factors, and cognitive decline in the Health and Retirement Study (HRS). *Aging and Mental Health*, **2020**, 24, 1479-1486	3.5	3
35	Characteristics of strokes associated with centrifugal flow left ventricular assist devices. *Scientific Reports*, **2021**, 11, 1645	4.9	3
34	P4-073: A PHARMACOGENETICS-SUPPORTED CLINICAL TRIAL TO DELAY ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE USING LOW-DOSE PIOGLITAZONE: AN UPDATE ON THE TOMORROW STUDY **2014**, 10, P809-P810		2
33	Managing genomic and proteomic knowledge. *Drug Discovery Today: Technologies*, **2005**, 2, 197-204	7.1	2
32	Use of resampling techniques to estimate the variance of parameters in pharmacological assays when experimental protocols preclude independent replication: an example using Schild regressions. *Journal of Pharmacological and Toxicological Methods*, **1995**, 34, 37-46	1.7	2
31	Drug and tissue factors both confound KA measurements. *Trends in Pharmacological Sciences*, **1990**, 11, 273-4	13.2	2
30	Motor Evoked Potentials Double Train Stimulation: Optimal Number of Pulses per Train. *Journal of Clinical Neurophysiology*, **2020**,	2.2	2
29	Disease-modifying effects of an structural variant in a predominantly ALS cohort. *Neurology: Genetics*, **2020**, 6, e470	3.8	2

28	Leisure Activities, , and Cognitive Decline: A Longitudinal Cohort Study. *Frontiers in Aging Neuroscience*, **2021**, 13, 736201	5.3	2
27	Socioeconomic Influence on Emergency Medical Services Utilization for Acute Stroke: Think Nationally, Act Locally. *Neurohospitalist, The*, **2021**, 11, 317-325	1.1	1
26	Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways. *Alzheimer's and Dementia*, **2021**, 17, 561-573	1.2	1
25	Association Between Polygenic Risk Score and the Progression from Mild Cognitive Impairment to Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2021**, 84, 1323-1335	4.3	0
24	A Triage Model for Interhospital Transfers of Low Risk Intracerebral Hemorrhage Patients. *Journal of Stroke and Cerebrovascular Diseases*, **2021**, 30, 105616	2.8	0
23	TOMM40-APOE haplotypes are associated with cognitive decline in non-demented Blacks. *Alzheimer's and Dementia*, **2021**, 17, 1287-1296	1.2	0
22	APOE, TOMM40, and sex interactions on neural network connectivity. *Neurobiology of Aging*, **2021**, 109, 158-165	5.6	0
21	Bioinformatics pipeline to guide late-onset Alzheimer's disease (LOAD) post-GWAS studies: Prioritizing transcription regulatory variants within LOAD-associated regions.. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2022**, 8, e12244	6	0
20	Polygenic Risk Score Effectively Predicts Depression Onset in Alzheimer's Disease Based on Major Depressive Disorder Risk Variants.. *Frontiers in Neuroscience*, **2022**, 16, 827447	5.1	0
19	Shared genetic etiology underlying late-onset Alzheimer's disease and post traumatic stress syndrome. *Alzheimer's and Dementia*, **2020**, 16, e041284	1.2	
18	A genetic enrichment strategy for delay of onset of Alzheimer's disease clinical trials. *Alzheimer's and Dementia*, **2020**, 16, e044920	1.2	
17	P4-284: GENETIC RELATIONSHIP OF APOE AND TOMM40 HAPLOTYPES IN AFRICAN AMERICAN, WEST AFRICAN, AND CAUCASIAN COHORTS **2014**, 10, P888-P888		
16	P3-021: IDENTIFICATION AND CHARACTERIZATION OF POLYMORPHIC STRUCTURAL VARIANTS ASSOCIATED WITH ALZHEIMER'S DISEASE AND DISEASES OF AGING **2014**, 10, P635-P635		
15	P3-018: Tomm40/ApoE variation and age of onset of mild cognitive impairment and dementia in a prospective, longitudinal study **2015**, 11, P626-P627		
14	[IC-P-066]: AD FAMILY HISTORY MODULATES EFFECTS OF TOMM40 523 POLY-T ON MTL ATROPHY AND HYPOMETABOLISM IN PRECLINICAL AND AD COHORTS **2017**, 13, P54-P55		
13	[P2065]: THE DISTINCT CONTRIBUTION OF SNCA-3?UTR TO PARKINSON's AND DEMENTIA WITH LEWY BODIES **2017**, 13, P629-P630		
12	[P4082]: ANALYSIS OF PLEIOTROPIC GENETIC EFFECTS ON COGNITIVE IMPAIRMENT AND SYSTEMIC INFLAMMATION IN THE HEALTH AND RETIREMENT STUDY **2017**, 13, P1290-P1291		
11	P2-061: A multi-modal comparison of biomarkers stratified by a simple genetic risk prediction algorithm **2015**, 11, P506-P506		

LIST OF PUBLICATIONS

| 10 | A mathematical model for analysis of pharmacologically induced changes in the kinetics of cardiac muscle. *Journal of Pharmacological and Toxicological Methods*, **1996**, 36, 171-83 | 1.7 |

| 9 | Clinical Trials of AD Delay of Onset: Enrichment by a Prognostic Genetic Biomarker. *Advances in Predictive, Preventive and Personalised Medicine*, **2013**, 141-160 | 0.4 |

| 8 | P4-293: APOE TOMM40 523 Haplotypes and the Risk of Alzheimer's Disease in Older Caucasian and African Americans **2016**, 12, P1146-P1146 |

| 7 | P4-295: TOMM40 523 Variant and Cognitive Decline in Community Based Older Persons with APOE E3/3 GENOTYPE **2016**, 12, P1146-P1147 |

| 6 | P3-070: ANALYSIS OF A SPORADIC MOUSE MODEL OF ALZHEIMER'S DISEASE **2018**, 14, P1091-P1091 |

| 5 | F2-03-01: UNTANGLING THE GENETIC COMPLEXITY OF LATE ONSET ALZHEIMER'S DISEASE **2018**, 14, P604-P605 |

| 4 | P2-616: LIGHT TO MODERATE ALCOHOL CONSUMPTION AND COGNITIVE DECLINE: FOCUS ON APOE-4 CARRIERS AND WOMEN IN THE HEALTH AND RETIREMENT STUDY **2018**, 14, P977-P977 |

| 3 | P3-116: ANALYSIS OF A SYSTEMIC INFLAMMATION-BASED POLYGENIC RISK SCORE ON EFFECTS ON COGNITIVE IMPAIRMENT IN THE HEALTH AND RETIREMENT STUDY **2018**, 14, P1112-P1112 |

| 2 | P4-041: BIOINFORMATICS APPROACH FOR IDENTIFYING ACTIVE ENHANCERS THAT DRIVE ALZHEIMER'S DISEASE GENETIC ETIOLOGY **2018**, 14, P1448-P1449 |

| 1 | APOE, TOMM40, and Sex Interactions on Neural Network Connectivity.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 12, e058171 | 1.2 |